Skip to main content
SpringerLink
Log in

Belimumab/guselkumab

Crohn's-disease and inflammatory bowel disease: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. "Country of occurrence, reporter country and primary source country not stated."

Reference

  • Hashmi S, et al. DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE (IBD) FOLLOWING THE USE OF BIOLOGIC TREATMENT FOR RHEUMATOLOGIC DISEASES: A REVIEW OF THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTS SYSTEM (FAERS). Gastroenterology 158 (Suppl. 1): S-959-S-960 abstr. Mo1879, No. 6, May 2020. Available from: URL: http://doi.org/10.1016/S0016-5085%2820%2933076-6 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Belimumab/guselkumab. Reactions Weekly 1809, 65 (2020). https://doi.org/10.1007/s40278-020-79849-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-79849-4

Search

Navigation